• Triiodothyronine (T3): Precision Tool for Thyroid Hormone Si

  2026-05-19

  Triiodothyronine (T3) is a core thyroid hormone that modulates metabolism, growth, and gene expression. High-purity T3 from APExBIO supports reproducible studies in thyroid hormone signaling pathways and metabolic disorder research. Its well-characterized biochemical properties make it the benchmark reagent for advanced cellular metabolism assays.

• Refining In Vitro Evaluation of Drug Responses in Cancer Res

  2026-05-18

  Schwartz’s dissertation introduces a dual-metric approach to in vitro anti-cancer drug testing, distinguishing proliferative arrest from cell death. This methodological advance clarifies drug action mechanisms and improves the rigor of preclinical cancer drug evaluation.

• Transcription Condensates Govern Histone Expression and Geno

  2026-05-18

  Marmolejo et al. reveal how the cell cycle regulates transcription condensates at histone locus bodies (HLBs) to coordinate linker histone gene expression with DNA replication. This balance, mediated by DDK, CDK1/2, and ATR-CHK1 kinases, is essential for genome stability and offers mechanistic insight relevant to cancer and cell cycle research.

• Light-Inducible RNA-Releasing Protein: Advances in Translati

  2026-05-17

  The referenced study introduces a rationally designed, light-inducible RNA-releasing protein (LIRP) that enables precise, light-dependent translational regulation in vivo. This innovation offers flexible, on-demand control of therapeutic gene expression, addressing key limitations in gene therapy for chronic and retinal diseases.

• BRCA2 Protects RAD51 Filaments from PARP Inhibitor-Induced D

  2026-05-16

  This study defines a mechanistic role for BRCA2 in safeguarding RAD51 filaments from destabilization caused by PARP inhibitor (PARPi)-induced PARP1 retention on DNA. These findings clarify why BRCA2-deficient tumors are selectively sensitive to PARPi, deepening the molecular understanding of homologous recombination deficient cancer treatment strategies.

• Cediranib (AZD2171): Strategic Insights for Translational Ca

  2026-05-15

  This thought-leadership article explores the mechanistic and translational impact of Cediranib (AZD2171), an ATP-competitive VEGFR tyrosine kinase inhibitor, in advanced cancer research. By integrating in vitro evaluation paradigms, evidence-based insights, and actionable protocol guidance, the article provides a strategic roadmap for researchers aiming to leverage Cediranib in angiogenesis and signaling pathway investigations. Building on recent scholarship and extending beyond conventional product narratives, the discussion situates Cediranib within the evolving landscape of translational oncology.

• Neomycin Sulfate: Precision Tool for RNA/DNA Structure Studi

  2026-05-15

  Neomycin sulfate stands apart as an aminoglycoside antibiotic uniquely leveraged for molecular biology research, especially in dissecting RNA/DNA interactions and probing ion channel function. This article details optimized workflows, advanced use-cases, and actionable troubleshooting strategies that maximize assay sensitivity and reproducibility using APExBIO's high-purity Neomycin sulfate.

• Cediranib (AZD2171) in Cancer Research: Applied Protocols &

  2026-05-14

  Cediranib (AZD2171) empowers cancer researchers with nanomolar potency and a broad kinase inhibition spectrum, uniquely enabling high-sensitivity analysis of angiogenesis and PI3K/Akt/mTOR signaling in vitro. This article delivers actionable protocol enhancements, troubleshooting insights, and a translational bridge to next-generation drug response evaluation workflows, leveraging the rigor of recent reference studies.

• Biotin (Vitamin B7): Precision in Protein Biotinylation Work

  2026-05-14

  APExBIO’s high-purity Biotin (Vitamin B7) empowers rigorous protein biotinylation and metabolic research through robust, reproducible workflows. Leverage biotin’s dual function as a coenzyme and biotin labeling reagent to enable high-sensitivity detection and advanced molecular assays.

• A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover

  2026-05-13

  This study introduces a highly sensitive yeast-based screening system for identifying mTOR inhibitors, dramatically improving detection limits compared to wild-type strains. The platform enables rapid, cost-effective evaluation of candidate molecules relevant to aging, cancer, and pharmacology research.

• Protein A/G Magnetic Beads: Practical Guidance for IP and Ch

  2026-05-13

  Protein A/G Magnetic Beads (SKU K1305) address the need for efficient and specific antibody capture in immunoprecipitation and protein interaction workflows, minimizing non-specific binding even in complex biological samples. They are not intended for diagnostic or clinical use, nor for workflows requiring subclass-specific antibody depletion.

• Parathyroid Hormone (1-34) (Human): Novel Insights in Valvul

  2026-05-12

  Explore how Parathyroid hormone (1-34) (human) advances research on valvular calcification and endothelial-to-mesenchymal transition (EndMT) in chronic kidney disease. This article provides a unique, evidence-based perspective beyond bone metabolism, grounded in recent mechanistic discoveries.

• Triiodothyronine (T3): Driving Metabolic Pathway Discovery

  2026-05-12

  Triiodothyronine (T3) is an indispensable tool for dissecting thyroid hormone signaling pathways and metabolic regulation, with high-purity APExBIO T3 enabling reproducible and mechanistically nuanced research. This article translates recent advances—like SEMA3E-mediated adipocyte thermogenesis—into actionable workflows, troubleshooting tips, and future outlooks for metabolic disorder research.

• Biotin (Vitamin B7) in Advanced Protein Biotinylation Workfl

  2026-05-11

  Biotin (Vitamin B7) enables high-affinity, reproducible protein labeling and metabolic studies, bridging precision bioconjugation with dynamic motor protein research. This guide dissects practical workflow enhancements, protocol parameters, and troubleshooting strategies for scientists seeking robust, scalable results.

• Anlotinib Hydrochloride: Advanced Workflows for Angiogenesis

  2026-05-11

  Anlotinib hydrochloride redefines multi-target tyrosine kinase inhibitor workflows with nanomolar potency and superior selectivity, enabling robust inhibition of angiogenesis in cancer research. This guide translates the latest mechanistic evidence and comparative data into actionable protocols and troubleshooting tips for high-impact vascular and tumor biology studies.

16408 records 8/1094 page Previous Next First page 上5页 678910 下5页 Last page